본문 바로가기

폐암 환자의 항암화학요법 유발성 호중구감소증 관련요인

Factors Related to Chemotherapy-Induced Neutropenia in Lung Cancer Patients

문서 유형
연구출판물 · 학술지 논문
등재
KCI
저널 순위
KCI Q4
피인용
KCI 0
ISSN
2233-5560

저자

  1. 진지혜제1저자부산대학교병원 간호사
  2. 박승빈교신저자부산대학교 간호대학 대학원생
  3. 강인순부산대학교 간호대학. 간호과학연구소 교수

초록

Purpose: This study aimed to identify the incidence of chemotherapy-induced neutropenia (CIN) and its associated factors in patients with lung cancer. Methods: Data from the electronic medical records of 181 patients with lung cancer who received their first cycle of chemotherapy at P University Hospital, City B, between January 1 and December 31, 2019, were analyzed. The collected data included general and clinical characteristics, treatment-related factors, hematologic parameters, and CIN-related variables. Statistical analysis was performed using SPSS software version 23.0, employing descriptive statistics, the x2 test, Fisher’s exact test, and logistic regression. Results: CIN occurred in 22.7% of the participants, of whom 7.3% developed febrile neutropenia (FN). The risk of CIN was 3.13 times higher in patients with mildly decreased glomerular filtration rate (GFR, 60-89 mL/min) than in those with normal GFR (≥90 mL/min, p=.007), and 2.69 times higher in patients treated with an etoposide and platinum regimen than in those who received other regimens (p=.019). The logistic regression model indicated a good fit (x2=2.53, p=.772), explaining 14.1% of the variance (Nagelkerke R2=.14). Conclusion: The risk of CIN was elevated among patients with mildly decreased GFR and those receiving etoposide along with platinum chemotherapy. Therefore, infection prevention education and close monitoring for signs of infection are essential for high-risk patients with impaired renal function to enable early detection and effective management of FN during the CIN period.

키워드

Lung neoplasmsAntineoplastic agentsChemotherapy-induced febrile neutropenia

식별자

KCI
ART003230564